Pegloticase (KRYSTEXXA) Infusion

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Weight: _____kg **Height:** _____cm

Allergies: _____

Diagnosis Code: _____

Treatment Start Date: _____ **Patient to follow up with provider on date:** _____

****This plan will expire after 365 days at which time a new order will need to be placed****

GUIDELINES FOR ORDERING

1. Send **FACE SHEET and H&P or most recent chart note**.
2. **Within 48 hours prior to each treatment, uric acid level must be obtained and results must be provided to the infusion clinic**. Anaphylaxis reactions have occurred. Risk of an infusion reaction is increased if patient uric acid is greater than 6 mg/dL. Discontinue treatment if levels exceed 6 mg/dL for 2 consecutive levels.
3. Prior to treatment initiation, Glucose-6-phosphate dehydrogenase (G6PD) serum test results must be included with these orders. Contraindication for G6PD deficiency, due to the risk of hemolysis and methemoglobinemia.
4. If patient misses 2 consecutive treatments (4 weeks), provider must approve continuing therapy or treatment will be discontinued.
5. **Patient must be given prescription for an EPINEPHrine auto-injector (EPIPEN) and instructed to bring one to each infusion appointment.**
6. Discontinue use of oral antihyperuricemic agents prior to initiating and during course of therapy
7. Gout Flares: Begin prophylaxis using nonsteroidal anti-inflammatory agents (NSAID) or colchicine, unless contraindicated, beginning at least 1 week before initiation of pegloticase and continuing for at least 6 months. An increase in gout flares is frequently observed. Gout flare-ups during treatment do not warrant discontinuation of therapy.
8. Congestive Heart Failure: Exercise caution in patients who have congestive heart failure and monitor patients closely following infusion.

PRE-MEDICATIONS: (Administer 30 minutes prior to infusion)

- ☐ acetaminophen (TYLENOL) tablet, 650 mg, oral, ONCE, every visit
- ☐ diphenhydrAMINE (BENADRYL) injection, 25 mg, intravenous, ONCE, every visit
- ☐ loratadine (CLARITIN) tablet, 10 mg, oral, AS NEEDED, every visit
  (Choose as alternative to diphenhydrAMINE if patient does not have a driver)
- ☐ methylPREDNISolone sodium succinate (SOLU-MEDROL), 40 mg, intravenous, ONCE, every visit

MEDICATIONS:

- pegloticase (KRYSTEXXA) 8 mg in 250 mL sodium chloride 0.9 %, intravenous, over 2 hours, ONCE, every visit

  Interval:
  - ☐ Every 2 weeks for ____ doses
  - ☐ Every 2 weeks until discontinued

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

NURSING ORDERS:

1. TREATMENT PARAMETERS - Hold treatment and notify provider:
    a. If G6PD results are not available prior to initiation
    b. If uric acid level is not obtained within 48 hours prior to each treatment or if uric acid is greater than 6 mg/dL (Treatment should be discontinued if 2 or more consecutive uric acid levels are greater than 6 mg/dL)
    c. If patient misses 2 consecutive treatments (4 weeks). Provider must approve continuing therapy or treatment will be discontinued
2. VITAL SIGNS – Monitor vital signs prior to pegloticase infusion, one hour into infusion, and at end of infusion.
3. The diluted pegloticase solution should be protected from light and used within 4 hours of dilution. Prior to administration, allow the diluted solution to reach room temperature. Do not warm to room temperature using any form of artificial heating.
4. Monitor patient closely for infusion reactions during pegloticase infusion and for 1 hour after the infusion. Advise patient that delayed hypersensitivity reactions may occur. For patients with heart failure, exacerbations can occur. Educate patient on signs and symptoms of infusion reaction, including skin rash, redness of skin, difficulty breathing, flushing, chest discomfort, chest pain, and rash.
5. Explain to patient that gout flares may initially increase when starting treatment, and medications to help reduce flares may need to be taken regularly for the first few months after therapy is started. Advise patient to continue therapy even if there are flares.
6. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.

AS NEEDED MEDICATIONS:

1. acetaminophen (TYLENOL) tablet, 650 mg, oral, EVERY 4 HOURS AS NEEDED for headache, fever, chills or malaise
2. diphenhydrAMINE (BENADRYL) capsule, 50 mg, oral, EVERY 4 HOURS AS NEEDED for itching

HYPERSENSITIVITY MEDICATIONS:

1. NURSING COMMUNICATION – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (Policy HC-PAT-133-GUD). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x1 dose for hypersensitivity reaction
3. EPINEPHrine HCl (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x1 dose for hypersensitivity reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity reaction
5. famotidine (PEPCID) 20 mg, intravenous, AS NEEDED x1 dose, for hypersensitivity reaction

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

By signing below, I represent the following:
I am responsible for the care of the patient (*who is identified at the top of this form*);
I hold an active, unrestricted license to practice medicine in: ☐ Oregon ☐ _____ (*check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon*);

My physician license Number is # _____ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature: _____ **Date/Time:** _____

Printed Name: _____ **Phone:** _____ **Fax**: _____

OLC Central Intake Nurse:

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient's preferred clinic location:

☐ **Beaverton**
OHSU Knight Cancer Institute
15700 SW Greystone Court
Beaverton, OR 97006
Phone number: 971-262-9000
Fax number: 503-346-8058

☐ **NW Portland**
Legacy Good Samaritan campus
Medical Office Building 3, Suite 150
1130 NW 22nd Ave.
Portland, OR 97210
Phone number: 971-262-9600
Fax number: 503-346-8058

☐ **Gresham**
Legacy Mount Hood campus
Medical Office Building 3, Suite 140
24988 SE Stark
Gresham, OR 97030
Phone number: 971-262-9500
Fax number: 503-346-8058

☐ **Tualatin**
Legacy Meridian Park campus
Medical Office Building 2, Suite 140
19260 SW 65th Ave.
Tualatin, OR 97062
Phone number: 971-262-9700
Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders